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ABSTRACT 
Training for accurate image interpretation is essential for the clinical use of β-amyloid 
positron emission tomography (PET) imaging, but the role of reader training and the accuracy 
of the algorithm for routine visual assessment of florbetaben PET scans are unclear. The aim 
of this study was to test the robustness of the visual assessment method for florbetaben scans, 
comparing efficacy readouts across different readers and training methods, and against a 
histopathology standard of truth (SoT). 
METHODS: Analysis was based on data from an international open-label, non-randomized, 
multicenter Phase 3 study in patients with or without dementia (ClinicalTrials.gov: 
NCT01020838). Florbetaben scans were assessed visually and quantitatively, and results 
were compared with amyloid plaque scores. For visual assessment, either in-person training 
(n=3 expert readers) or an electronic training method (n=5 naïve readers) was used. Brain 
samples from participants who died during the study were used to determine the 
histopathological SoT using Bielschowsky silver staining (BSS) and immunohistochemistry 
for β-amyloid plaques. 
RESULTS: Data were available from 82 patients who died and underwent post-mortem 
histopathology. Comparing visual assessment results with BSS+immunohistochemistry as 
SoT, median sensitivity was 98.2% for the in-person trained readers and 96.4% for the e-
trained readers, while median specificity was 92.3% and 88.5%, respectively. Median 
accuracy was 95.1% and 91.5%, respectively. Based on BSS only as the SoT, median 
sensitivity was 98.1% and 96.2%, respectively, median specificity was 80.0% and 76.7%, and 
median accuracy was 91.5% and 86.6%. Inter-reader agreement (Fleiss’ kappa) was excellent 
(0.89) for in-person-trained readers and very good (0.71) for e-trained readers. Median intra-
reader agreement was 0.9 for both in-person and e-trained readers. Visual and quantitative 
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assessments were concordant in 88.9% of scans for in-person trained readers and in 87.7% of 
scans for e-trained readers.  
CONCLUSION: Visual assessment of florbetaben images was robust in challenging scans 
from elderly end-of-life individuals. Sensitivity, specificity, and inter-reader agreement were 
high, independent of expertise and training method. Visual assessment was accurate and 
reliable for detection of plaques using BSS and immunohistochemistry, and well correlated 
with quantitative assessments. 
 
Key words: Alzheimer’s disease, florbetaben, positron-emission tomography 
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INTRODUCTION 
Florbetaben is an 18F-labeled β-amyloid tracer developed for positron emission tomography 
(PET). In 2014, florbetaben was approved by the US Food and Drug Administration, the 
European Medicines Agency and the Korean Ministry of Food and Drug Safety (MFDS) to 
detect or exclude the presence of neuritic β-amyloid plaques in brain (1,2). In a Phase III 
study, high sensitivity and specificity were demonstrated for florbetaben in the detection of β-
amyloid aggregates comparing PET with post-mortem histopathology (3). 
The current clinical method for interpretation of florbetaben β-amyloid PET scans is 
visual assessment (4). Training for accurate image interpretation is a key issue for β-amyloid 
PET imaging – all readers require training and several different training tools are available. 
The type of reader training and the accuracy for visual assessment of florbetaben PET scans 
are unclear. In order to test the adequacy of the training comparing visual assessment against 
β-amyloid histopathology, scans from end-of-life patients are required. It is known that 
pronounced atrophy and other brain abnormalities can compromise image interpretation in 
end-of-life individuals. Indeed, severe structural brain abnormalities were present in the 
participants in the histopathology cohort, leading to challenging scans. If acceptable images 
can be obtained under these conditions, improved reads can be expected in the clinical setting 
with less technically challenging scans. Moreover, a technically difficult dataset would be 
likely to expose differences between training approaches (electronic training tool vs. in-
person trainer) that might inform best training practices. 
The aim of the present study was to test the robustness of the visual assessment 
method for florbetaben scans, comparing efficacy readouts (sensitivity, specificity, and kappa 
values) across different readers and training methods, against a histopathology standard of 
truth (SoT) in end-of-life patients. The study also compared visual and quantitative 
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assessments of florbetaben PET, since quantification is commonly used in research and may 
be implemented in future clinical routine. 
MATERIALS AND METHODS 
Study design and population 
This analysis was based on an international open-label, non-randomized, multicenter 
Phase 3 study (ClinicalTrials.gov: NCT01020838). The study was conducted in accordance 
with the Declaration of Helsinki, and approvals from regulatory authorities and ethics 
committees were obtained. 
Participants were recruited from 15 centers (including dementia clinics with brain-
bank experience, hospices, private practices, and dementia self-help groups) in Australia, 
Europe, Asia, and North America, and examined between February 2010 and August 2013. 
Eligible subjects were non-demented individuals, n=9, and patients with Alzheimer’s disease 
(AD), n=60, dementia with Lewy bodies (DLB), n=4, or other dementias, n=9. Key exclusion 
criteria were cerebral large-vessel disease, brain tumors, and cardiovascular instability 
requiring intensive care or therapeutic intervention. All participants (or their legal 
representatives) provided written informed consent to undergo brain MRI, a PET scan with 
florbetaben, and to donate their brain for post-mortem examination. Details of the study 
methods have been presented previously (3). 
Brain Image Data Acquisition 
PET images were acquired 90–110 minutes after intravenous injection of 300 MBq ± 
20% florbetaben (5) according to a standardized acquisition and image-processing protocol 
established during a technical visit to each center. Three-dimensional volumetric T1-
weighted brain MRI (e.g. magnetization prepared rapid gradient echo or spoiled gradient 
recalled sequences) were collected.  
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Study design  
Florbetaben scans were assessed visually and quantitatively, and results compared 
with β-amyloid presence/absence in pathology. For visual assessment, either in-person 
training (n=3 expert readers) or an electronic training (e-training) method (n=5 naïve readers) 
was used. Composite standardized uptake value ratios (SUVRs) were determined (6), and 
receiver operating characteristic curve analysis used to ascertain the optimal threshold for the 
sensitivity/specificity calculations. The composite SUVR providing the highest sum of 
sensitivity and specificity was selected as cut-off value. 
Visual assessment method 
The in-person expert training and electronic training modules were identical in 
approach and content (6,7). The training emphasized normal white matter anatomy using 
structural MRI and coregistered florbetaben PET images to appreciate white matter - gray 
matter boundaries since a positive scan demonstrates extension of radiotracer uptake beyond 
the cortical white matter to adjacent gray matter in key brain regions. Specifically, readers 
used a regional cortical tracer uptake scoring system (RCTU) (1 = no tracer uptake, 2 = 
moderate tracer uptake, 3 = pronounced tracer uptake) in four brain areas: lateral temporal 
cortex, frontal cortex, posterior cingulate cortex/precuneus, parietal cortex (see figure 1 for 
details). The resulting scores condense into a binary interpretation (score 1 = negative; score 
2 or 3 = positive). A RCTU score of 1 in each brain region led to a brain amyloid plaque load 
(BAPL) score of 1, a RCTU score of 2 in any brain region and no score 3 led to a BAPL 
score of 2. A RCTU score of 3 in any of the 4 brain regions led to a BAPL of 3. 
No access to other scan orientations (i.e. coronal, sagittal), and no reorientation or 
structural information from computed tomography (CT) or magnetic resonance imaging 
(MRI) was available to readers. Readers viewed scans in gray scale only. There were some 
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minor differences between the training, as the trainees could not ask questions of an expert 
reader during the review with the electronic training tool.  
All images were assessed by eight readers: three in-person trained experts and five 
naïve readers trained using an e-training tool. All readers were nuclear medicine physicians. 
The ”expert reader” was defined as having direct experience with PET amyloid scans. The 
naïve reader had no experience with the visual assessment method and was not involved in 
any pivotal study using an 18F-labeled amyloid imaging agent. 
Quantitative assessment method 
Brain PET image quantification was performed using a standardized volume of 
interest template applied to the spatially normalized grey matter PET image based on a 
gray/white/cerebrospinal fluid segmentation of the participant’s T1-weighted volumetric MRI 
(6). A region of interest template (6) sampled the lateral temporal, frontal, anterior and 
posterior cingulate gyrus/precuneus, and parietal lobes which were averaged to determine a 
composite SUVRs calculated using the cerebellar cortex as the reference tissue. 81 of the 82 
brains were evaluated in this fashion; in one scan the segmentation process failed owing to 
poor technical quality of the MRI. 
Pathology standard of truth 
Brain samples from 82 participants who died during the study were used to determine 
the histopathological SoT. Six brain regions were examined with both Bielschowsky silver 
staining (BSS) and immunohistochemistry for the β-amyloid protein: middle frontal gyrus, 
occipital cortex, hippocampus/parahippocampal gyrus, anterior cingulate cortex, posterior 
cingulate cortex/precuneus, and cerebellar cortex.  
The presence of amyloid plaques was assessed by a blinded histopathology consensus 
panel of three expert neuropathologists using two different methods: Bielschowsky silver 
staining (BSS) and immunohistochemistry for β-amyloid. For the analysis presented here 
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only neuritic plaques and cored plaques were considered. Neuritic plaque density (as detected 
by BSS) was assessed according to the Consortium for Establishing a Registry for Alzheimer 
Disease (CERAD) criteria  (8), providing a semi-quantitative score with the categories 
“absent”, “sparse”, “moderate”, or “frequent”.  The same semi-quantitative categories were 
used to score the number of cored plaques detected by β-amyloid immunohistochemistry. β-
amyloid was regarded as present in a given brain region when sufficient neuritic or cored 
plaques were present to achieve a score of “moderate” or “frequent”. 
Importantly, BSS is not specific for β-amyloid deposits and also has some technical 
limitations that may hinder the identification of some neuritic plaques in AD (9). The 
combination of BSS and immunohistochemistry for β-amyloid is recommended in current 
neuropathologic guidelines for assessment of AD pathology (10,11).  Therefore, both BSS 
and BSS+immunohistochemistry data were used for further analyses. 
Statistical analysis 
Sensitivity, specificity and accuracy were evaluated by comparing visual assessments 
with the histopathological SoT. Independent Mann-Whitney tests were performed to compare 
the reported parameters between training groups. Reliability of visual assessment was 
evaluated by Cohens’ and Fleiss’ kappa. To investigate the intra-reader agreement, a random 
subsample of images (22 for the in-person trained group and 20 for the e-trained) was re-read 
by all readers. The association between quantitative and visual assessments was evaluated 
with a Chi squared test. 
RESULTS 
Study population and post-mortem β-amyloid histopathology 
In total, 205 end-of-life individuals underwent florbetaben PET imaging (52% male; 
mean age, 76.9 ± 11 [range, 48–98] years). As of August 2013, 82 participants had died and 
undergone autopsy and post-mortem histopathology (clinical diagnoses: AD, n=60; DLB, 
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n=4; other dementias, n=9; non-demented, n=9). Comparison of clinical diagnosis of AD and 
β-amyloid pathology (BSS+immunohistochemistry as SoT) revealed a discordance in some 
patients with AD, with 13 of the 60 patients with a clinical diagnosis of probable AD were 
found to be β-amyloid negative. Of the four subjects with DLB as clinical diagnosis, two 
were β-amyloid positive. Seven of the nine subjects clinically classified as other dementia 
were β-amyloid negative. 4 of the 9 non-demented healthy elderly subjects were β-amyloid 
positive. In total, of the 82 brains examined by histopathology, 56 were β-amyloid positive 
and 26 were β-amyloid negative with BSS+immunohistochemistry as SoT. Using BSS alone, 
52 brains were β-amyloid positive and 30 β-amyloid negative. 
Sensitivity and specificity of the visual assessment 
Of the 82 PET scans assessed in this study, 81 were classified equally by both training 
groups. With BSS+immunohistochemistry as SoT, a median (range) sensitivity of 98.2% 
(94.6–98.2%) was obtained for the three in-person trained readers and 96.4% (91.1–100%) 
for the five e-trained readers. With BSS alone, median (range) sensitivity was 98.1% (96.2–
98.1) and 96.2% (90.4–100%), respectively (Table 1). With BSS+immunohistochemistry, 
median (range) specificity was 92.3% (88.5–92.3%) for the in-person trained readers and 
88.5% (53.9–92.3%) for the e-trained readers, whereas BSS alone led to 80.0% (76.7–83.3%) 
and 76.7% (46.7–80%), respectively (Table 1). Median (range) accuracy with 
BSS+immunohistochemistry was 95.1% (93.9–96.3%) for in-person trained readers and 
91.5% (84.1–93.9%) for e-trained readers. BSS alone as SoT had a median accuracy of 
91.5% (90.2–91.5%) for in-person trained readers and 86.6% (79.3–89%) for e-trained 
readers (Table 1). Independent Mann-Whitney tests were performed to compare the reported 
parameters between training groups. No statistical differences were found for sensitivity and 
specificity, independent of the SoT. Accuracy was higher for expert in-person trained readers 
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than for the e-trained readers (p=0.03) (Table 1). Individual reader results of visual 
assessments are provided in supplementary Table 1. 
Inter- and intra-reader agreement 
Inter-reader agreement (Fleiss’ kappa) was 0.89 (considered excellent, 95% 
confidence interval [CI]: 0.82, 0.97) for expert in-person-trained readers and 0.71 (considered 
very good, 95% CI: 0.62, 0.81) for naïve e-trained readers (Table 2). Median (range) intra-
reader agreement was 0.9 (0.79–0.90) for expert in-person trained readers and 0.9 (0.66–1.00) 
for e-trained readers (Table 3). 
Comparison of visual and quantitative assessments 
81 of 82 images were evaluated with both quantitative and visual methods by the in-
person trained readers and e-trained readers. Receiver operating characteristic curve analysis 
of composite grey matter SUVRs resulted in an optimal cut-off of 1.47 with  a sensitivity of 
85.7% (95% CI, 73.8–93.6%) and a specificity of 92.0% (95% CI, 74.0–99.0%.  87.7% 
(n=71) of the scans were classified as positive or negative by both the e-trained readers and 
quantitative approaches, with the remaining 12.3% (n=10) of scans showing a discrepancy 
between the two approaches. Both methods (visual assessment by five e-trained readers and 
SUVR quantification) were significantly and strongly related (Χ2=44.19, p<0.0001, Kappa = 
0.73; Table 4, Figure 2A). Similarly, for in-person trained readers; 88.9% (n=72) of 
assessments were concordant and 11.1% (n=9) were discordant with quantitation, with 
significant relationship between methods (Χ2 = 47.33, p<0.0001, Kappa = 0.76; Table 5, 
Figure 2B). 
Further details of the 10 discordant cases are summarized in Table 6. Concordance 
with the pathology results was found with visual assessment in 9 cases by in-person trained 
readers, in 8 cases by e-trained readers, but with the quantitative assessment only 2 cases 
matched the pathology results.  Marked atrophy was found in 7 cases, all with visual 
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assessment matching pathology results (6 positive and one negative case). However, for the 7 
marked atrophy cases none of the quantitative assessment results matched with pathology, 
showing SUVRs < 1.47 in the 6 positive cases and SUVR of 1.52 in the negative case with 
marked atrophy. Reader agreement for 8 of 10 cases was very high both for the in-person and 
electronically trained reader groups. Only for one subject (case # 75 in table 6, supplementary 
table 1) the visual assessments did differ for the two methods. 
Challenging cases 
The patient cohort included challenging cases, such as subjects with marked brain 
atrophy or scans with head motion. Figure 3 shows sample florbetaben PET scans from a 
patient with marked brain atrophy, with potential for false-positive assessment. A small 
percentage of scans demonstrated motion as illustrated in Figure 4. 
DISCUSSION 
Results from this study demonstrate high sensitivity and specificity of florbetaben 
PET imaging for evaluation of β-amyloid plaques in end-of-life individuals. Importantly, the 
sensitivity and specificity were independent of the read training method, the previous 
expertise of readers in β-amyloid PET scan assessment, and the histopathology method used 
(BSS with or without immunohistochemistry). However, specificity increased for 
BSS+immunohistochemistry compared with BSS alone, as four brains in the 
BSS+immunohistochemistry group were additionally categorized as β-amyloid positive. 
Indeed, BSS+immunohistochemistry is recommended in current neuropathological guidelines 
for assessment of AD pathology (10,11). Intra-reader and inter-reader agreement was very 
high for both training groups. 
The individual differences in sensitivity and specificity amongst the five 
inexperienced readers are particularly informative. There was a wide range of specificity in 
particular, with two readers showing relatively lower performance than the other three. Post-
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study interviews with each individual reader suggested that those with poorer performance 
were less rigid in the application of the training rules to their visual assessments. Specifically, 
when assessing whether a particular region is positive, the algorithm requires that the 
majority (i.e. at least 50%) of the axial slices comprising each region must be positive. In 
some instances, the poorer readers did not apply this rule systematically, leading to a region 
being classified as positive. Nonetheless, the sensitivity and specificity in the present study 
were consistent with earlier analyses from the same study (3) and also with previous reports 
using florbetaben PET  (6,12) using clinical diagnosis as the SoT. Pathology examinations 
have shown, however, that clinical diagnosis of AD can be wrong (i.e. individuals diagnosed 
with AD dementia who do not show β-amyloid plaques upon autopsy) in 10–30 % of cases 
(13). This can lead to false-negatives compromising the sensitivity estimation when using 
clinical diagnosis as SoT. 
The relationship of visual reads to quantitative values was also consistent with prior 
reports (6,14), indicating high concordance between visual positivity and negativity and the 
composite SUVR using a quantitative cut-off for positive and negative scans. There were 
only few cases (10 for e-trained and 9 for in-person trained out of 81 case evaluations) in 
which there was discordance between visual and quantitative assessments. The visual 
assessment method used did not allow comparison of the PET scan images with CT or MR. 
This may lead to difficulties in the interpretation of some cases with atrophy, and 
quantification could potentially help here. Most of the visual vs quantitative discordant cases 
showed marked atrophy. However, in this study the visual assessment of discordant cases 
matched with pathology results. Quantitative assessment of cases with marked atrophy were 
all discordant with pathology results. The readers were more adept at distinguishing gray 
matter from white matter uptake in scans with severe atrophic changes than the quantification 
method. Two exceptions to this are shown in figures 1 and 2 in the supplementary material. 
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This suggests that atrophy may affect the quantification method used in this study more than 
the visual assessment. Further investigation is required to substantiate this and whether partial 
volume error correction influences this result. 
The end-of-life population used in this study is not the intended population for β-
amyloid PET scanning. The clinically intended population will likely have less structural 
brain abnormalities observed in this study cohort. Furthermore, the reading methodology 
designed for florbetaben in the present study was quite restrictive, with readers not permitted 
to use all the tools routinely available in nuclear medicine for PET assessment (3). In clinical 
practice, PET scans are read using three spatial orientations, with structural images provided 
by CT or MRI to guide anatomical localization of findings, often in discontinuous color 
scales for fused images. Additional use of all available tools for image reading will likely 
increase the diagnostic performance. Nevertheless, excellent results were obtained even 
allowing for the challenging nature of some scans and the stringent requirements of the 
applied reading methodology. 
CONCLUSION 
Overall, visual assessment of florbetaben images was robust even in challenging scans 
from elderly end-of-life individuals. Sensitivity and specificity were high, as was inter-reader 
agreement, independent of the reader expertise and training method employed. The visual 
assessment strategy and respective training tools to analyze florbetaben PET scans are 
accurate and reliable in the detection of brain neuritic β-amyloid plaques as assessed using 
BSS, and cored plaques as assessed using immunohistochemistry, and showed a good 
correlation with quantitative assessments. 
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Figure 1. Visual patterns of abnormality and normality taught to readers using an electronic 
training tool or during in-person training. Cerebellum: A contrast between the white matter 
(arrows) and grey matter is seen in both negative and positive scans. Extracerebral tracer 
uptake in scalp and in the posterior sagittal sinus (arrowhead) can be seen. Lateral temporal 
lobes: The positive scan shows a “plumped”, smooth appearance of the outer border of the 
brain (dashed line) from tracer uptake in the grey matter. Spiculated or “mountainous” 
appearance of the white matter (arrows) characterizes the negative scan. Frontal lobes: The 
positive scan shows the tracer uptake has a “plumped”, smooth appearance due to the grey 
matter signal (dashed line). Spiculated appearance of the white matter in the frontal lobes 
(arrows) is seen in the negative scan. Posterior cingulate / precuneus: Adjacent to the 
splenium (arrow), the region appear as a hypo-intense “hole” (circle) in the negative scan, 
whereas this hole is absent (circle) in the positive scan. Parietal lobes: In the positive scan, 
the midline between the parietal lobes is thinner. The cortical areas are “filled-up” and show 
smoother appearance as the uptake extends to the outer rim. In the negative scan, the midline 
between the parietal lobes can be easily identified (long arrow); white matter has spiculated 
appearance (short arrow) with less uptake to the outer rim (dashed line).  
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Figure 2. Comparison of visual and quantitative image assessment. Visually assessed images 
were based on the majority results classified into V+ (visual positive scan) and V- (visual 
negative scan). Assessment data is plotted related to composite SUVR and subject age 
(years). A) Depicts the majority read data of the electronically trained readers and, B) shows 
majority read data of the in-person trained readers.  
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Figure 3. Florbetaben a) PET and b) MRI scans from patient # 71 with marked brain atrophy, 
which was assessed by all readers as β-amyloid positive. The patient was found to be β-
20 
 
amyloid negative on post-mortem histopathology and positive in the quantitative assessment 
(SUVR = 1.53). 
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Figure 4. Florbetaben a) PET and b) MRI scans from patient # 68 with motion artifact, 
potentially leading to a false-positive visual assessment. All readers assessed the scans as β-
22 
 
amyloid negative. The patient was found to be β-amyloid negative on post-mortem 
histopathology and negative on the quantitative assessment (SUVR = 1.10). 
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Table 1. Sensitivity, specificity and accuracy of visual florbetaben PET scan reads in the eight readers (n=82 scans).  
 
 
BSS BSS /IHC 
Reader Sensitivity (95% CI) Specificity (95% CI) Accuracy   (95% CI) Sensitivity (95% CI) Specificity (95% CI) Accuracy   (95% CI) 
In-person 
training 
1 96.2 (90.9-100.0) 83.3 (70.0-96.7) 91.5 (85.4-97.5) 94.6 (88.7-100.0) 92.3 (82.1-100.0) 93.9 (88.7-99.1) 
2 98.1 (94.3-100.0) 76.7 (61.5-91.8) 90.2 (83.8-96.7) 98.2 (94.7-100.0) 88.5 (76.2-100.0) 95.1 (90.5-99.8) 
3 98.1 (94.3-100.0) 80.0 (65.7-94.3) 91.5 (85.4-97.5) 98.2 (94.7-100.0) 92.3 (82.1-100.0) 96.3 (92.3-100.0) 
Electronic 
media 
training 
1 94.2 (87.9-100.0) 80.0 (65.7-94.3) 89.0 (82.3-95.8) 92.9 (86.1-99.6) 88.5 (76.2-100.0) 91.5 (85.4-97.5) 
2 98.1 (94.3-100.0) 46.7 (28.8-64.5) 79.3 (70.5-88.0) 98.2 (94.7-100.0) 53.8 (34.7-73.0) 84.1 (76.2-92.1) 
3 90.4 (82.4-98.4) 80.0 (65.7-94.3) 86.6 (79.2-94.0) 91.1 (83.6-98.5) 92.3 (82.1-100.0) 91.5 (85.4-97.5) 
4 96.2 (90.9-100.0) 76.7 (61.5-91.8) 89.0 (82.3-95.8) 96.4 (91.6-100.0) 88.5 (76.2-100.0) 93.9 (88.7-99.1) 
5 100.0 56.7- (38.9-74.4) 84.1- (76.2-92.1) 100.0 65.4 (47.1-83.7) 89.0 (82.3-95.8) 
Statistics p-value 0.64 0.28 0.03 0.76 0.21 0.05 
 BSS = Bielschowsky silver staining; IHC = immunohistochemistry; Statistics = Independent Mann-Whitney tests 
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Table 2. Inter-reader Cohen’s kappa values* (95% confidence intervals) 
 In-person training  Electronic media training 
In-person 1 2 3 
Electronic 
media 
1 2 3 4 5 
1 x 
0.93 
(0.85–1.00) 
0.89 
(0.79–0.98) 
1 x 
0.57 
(0.38–0.75) 
0.87  
(0.76–0.97) 
0.91  
(0.82–1.00) 
0.63  
(0.45–0.80) 
2 
 x 
0.86 
(0.75–0.97) 
2 
 x 
0.53  
(0.34–0.71) 
0.66  
(0.48–0.83) 
0.75  
(0.59–0.92) 
3 
  x 3   x 
0.86  
(0.76–0.97) 
0.58  
(0.41–0.76) 
    
4 
   x 
0.71  
(0.56–0.87) 
    
5 
    x 
*Kappa values in the range 0.81–1.00 are considered excellent, 0.61–0.80 very good, and 0.41–0.60 moderate
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Table 3. Intra-reader Cohens’ kappa values 
 Reader Cohen’s kappa (and 95% CI) 
In-person Training (n=22) 1 0.90 (0.72 - 1.00) 
2 0.90 (0.71 - 1.00) 
3 0.79 (0.51 - 1.00) 
Electronic media Training (n=20) 1 1.00 (1.00 - 1.00) 
2 0.66 (0.30 - 1.00) 
3 0.90 (0.71 - 1.00) 
4 0.90 (0.70 - 1.00) 
5 1.00 (1.00 - 1.00) 
CI = confidence interval 
 
Table 4. Electronically trained visual assessment in comparison to composite SUVR 
quantification. 
 Quantitative assessment 
Positive Negative Total 
Visual assessment    
Positive 48 8 56 
Negative 2 23 25 
Total 50 31 81 
 
Table 5. In-person visual assessment in comparison to composite SUVR quantification. 
 Quantitative assessment 
Positive Negative Total 
Visual assessment    
Positive 48 7 55 
Negative 2 24 26 
Total 50 31 81 
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Table 6. Comparison of visual versus (semi)quantitative analysis for discordant cases (i.e. cases visually read as positive but quantified as 
negative or visually read as negative and quantified as positive). 
Case Age Visual in-person trained Visual e-trained 
Quanti-
fication SUVR PET evaluation 
Histopathology 
(BSS+IHC) Clinical diagnosis 
   Agreement  Agreement      
3 82 positive 100% positive 100% negative 1.01 Marked atrophy positive AD 
5 90 positive 100% positive 100% negative 1.02 Marked atrophy positive AD 
39 82 positive 100% positive 100% negative 1.42 Marked atrophy positive AD 
40 70 positive 100% positive 100% negative 1.14 --- positive Other dementia 
43 92 positive 100% positive 80% negative 1.18 Marked atrophy positive AD 
44 72 positive 100% positive 100% negative 1.14 Marked atrophy positive AD 
45 91 positive 100% positive 100% negative 1.45 Marked atrophy positive AD 
75 81 negative 67% positive 80% negative 1.17 --- negative AD 
22 98 negative 67% negative 80% positive 1.67 --- positive AD 
67 83 negative 100% negative 80% positive 1.52 Marked atrophy negative Other dementia 
AD = Alzheimer’s disease, Agreement = Inter-reader agreement within training group, PET evaluation = additional PET assessment conducted after initial 
study.  
 




